HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

NCT02947152 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer
Renal Cell Carcinoma

Interventions

DRUG: HKT288

Sponsor

Novartis Pharmaceuticals